Recently added

ENDOLUNG trial, part II. A phase II study of the Akt/mTOR inhibitor and autophagy inducer ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with squamous non-small cell lung cancer

Estévez-García, Purificación; Martin Martorell, Paloma; Sais, Elia; Bosch-Barrera, Joaquim; Sabatier, Renaud; Nadal, Ernest; OAKNIN, ANA (Elsevier, 2025-03)

A phase I, first-in-human trial of KO-947, an ERK1/2 inhibitor, in patients with advanced solid tumors

Adjei, Alex A.; Olszanski, Anthony; Francis, Jasmine; Schram, Alison; Boni, Valentina; Vieito , Maria; GARRALDA, Elena (Elsevier, 2025-03)

Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib plus best supportive care: results from FRESCO-2

Stintzing, Sebastian ; Satoh, Taroh; Eng, Cathy; Elez, Elena; Tabernero, Josep; Dasari, Arvind; Lonardi, Sara (Elsevier, 2025-03)

STELLAR-304: a phase III study of zanzalintinib (XL092) plus nivolumab in advanced non-clear cell renal cell carcinoma

Pal, Sumanta; Kanesvaran, Ravindran; Molina-Cerrillo, Javier; Feldman, Darren; Barata, Pedro; Powles, Thomas; Suárez, Cristina (Taylor & Francis, 2025-02-26)

The efficacy and safety of mirvetuximab soravtansine in FRα-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trial

Secord, Angeles; Lewin, Sharyn; Murphy, Conleth; Barquin, Arantzazu; Gálvez Montosa, Fernando; Cecere, Sabrina Chiara; OAKNIN, ANA (Elsevier, 2025-03)

Scientia. Department of Health Digital Information Depot

Vall d'Hebron Institut d'Oncologia - VHIO: Recent submissions

ENDOLUNG trial, part II. A phase II study of the Akt/mTOR inhibitor and autophagy inducer ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with squamous non-small cell lung cancer

A phase I, first-in-human trial of KO-947, an ERK1/2 inhibitor, in patients with advanced solid tumors

Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib plus best supportive care: results from FRESCO-2

STELLAR-304: a phase III study of zanzalintinib (XL092) plus nivolumab in advanced non-clear cell renal cell carcinoma

The efficacy and safety of mirvetuximab soravtansine in FRα-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trial

Scientia. Department of Health Digital Information Depot

Vall d'Hebron Institut d'Oncologia - VHIO: Recent submissions

ENDOLUNG trial, part II. A phase II study of the Akt/mTOR inhibitor and autophagy inducer ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with squamous non-small cell lung cancer ﻿

A phase I, first-in-human trial of KO-947, an ERK1/2 inhibitor, in patients with advanced solid tumors ﻿

Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib plus best supportive care: results from FRESCO-2 ﻿

STELLAR-304: a phase III study of zanzalintinib (XL092) plus nivolumab in advanced non-clear cell renal cell carcinoma ﻿

The efficacy and safety of mirvetuximab soravtansine in FRα-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trial ﻿

ENDOLUNG trial, part II. A phase II study of the Akt/mTOR inhibitor and autophagy inducer ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with squamous non-small cell lung cancer

A phase I, first-in-human trial of KO-947, an ERK1/2 inhibitor, in patients with advanced solid tumors

Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib plus best supportive care: results from FRESCO-2

STELLAR-304: a phase III study of zanzalintinib (XL092) plus nivolumab in advanced non-clear cell renal cell carcinoma

The efficacy and safety of mirvetuximab soravtansine in FRα-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trial